|
1
|
Mizrahi JD, Surana R, Valle JW and Shroff
RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spath C, Nitsche U, Muller T, Michalski C,
Erkan M, Kong B and Kleeff J: Strategies to improve the outcome in
locally advanced pancreatic cancer. Minerva Chir. 70:97–106.
2015.PubMed/NCBI
|
|
3
|
Krüger K, Büning C and Schriever F:
Activated T lymphocytes bind in situ to stromal tissue of colon
carcinoma but lack adhesion to tumor cells. Eur J Immunol.
31:138–145. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Whole genomes redefine the mutational landscape of pancreatic
cancer. Nature. 518:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moffitt RA, Marayati R, Flate EL, Volmar
KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung
AH, et al: Virtual microdissection identifies distinct tumor- and
stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat
Genet. 47:1168–1178. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bailey P, Chang DK, Nones K, Johns AL,
Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC,
et al: Genomic analyses identify molecular subtypes of pancreatic
cancer. Nature. 531:47–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herskind C, Talbot CJ, Kerns SL, Veldwijk
MR, Rosenstein BS and West CM: Radiogenomics: A systems biology
approach to understanding genetic risk factors for radiotherapy
toxicity? Cancer Lett. 382:95–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoshino I and Yokota H: Radiogenomics of
gastroenterological cancer: The dawn of personalized medicine with
artificial intelligence-based image analysis. Ann Gastroenterol
Surg. 5:427–435. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kickingereder P, Bonekamp D, Nowosielski
M, Kratz A, Sill M, Burth S, Wick A, Eidel O, Schlemmer HP,
Radbruch A, et al: Radiogenomics of glioblastoma: Machine
learning-based classification of molecular characteristics by using
multiparametric and multiregional MR imaging features. Radiology.
281:907–918. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Attiyeh MA, Chakraborty J, McIntyre CA,
Kappagantula R, Chou Y, Askan G, Seier K, Gonen M, Basturk O,
Balachandran VP, et al: CT radiomics associations with genotype and
stromal content in pancreatic ductal adenocarcinoma. Abdom Radiol
(NY). 44:3148–3157. 2019. View Article : Google Scholar
|
|
11
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iwatate Y, Hoshino I, Yokota H, Ishige F,
Itami M, Mori Y, Chiba S, Arimitsu H, Yanagibashi H, Nagase H and
Takayama W: Radiogenomics for predicting p53 status, PD-L1
expression, and prognosis with machine learning in pancreatic
cancer. Br J Cancer. 123:1253–1261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. Wiley;
Chichester: 2017
|
|
14
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arcangeli A, Crociani O and Bencini L:
Interaction of tumour cells with their microenvironment: Ion
channels and cell adhesion molecules. A focus on pancreatic cancer.
Philos Trans R Soc Lond B Biol Sci. 369:201301012014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar
|
|
17
|
Brown NF and Marshall JF:
Integrin-Mediated TGFβ activation modulates the tumour
microenvironment. Cancers (Basel). 11:12212019. View Article : Google Scholar
|
|
18
|
Marsh D, Dickinson S, Neill GW, Marshall
JF, Hart IR and Thomas GJ: alpha vbeta 6 Integrin promotes the
invasion of morphoeic basal cell carcinoma through stroma
modulation. Cancer Res. 68:3295–3303. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Margadant C and Sonnenberg A:
Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing.
EMBO Rep. 11:97–105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheuk IW, Siu MT, Ho JC, Chen J, Shin VY
and Kwong A: ITGAV targeting as a therapeutic approach for
treatment of metastatic breast cancer. Am J Cancer Res. 10:211–223.
2020.
|
|
21
|
Linhares MM, Affonso RJ Jr, Viana Lde S,
Silva SR, Denadai MV, de Toledo SR and Matos D: Genetic and
immunohistochemical expression of integrins ITGAV, ITGA6, and ITGA3
as prognostic factor for colorectal cancer: Models for global and
disease-free survival. PLoS One. 10:e01443332015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang H, Chen H, Jiang Z, Lin Y, Wang X,
Xiang J and Peng J: Integrin subunit alpha V promotes growth,
migration, and invasion of gastric cancer cells. Pathol Res Pract.
215:1525312019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Horioka K, Ohuchida K, Sada M, Zheng B,
Moriyama T, Fujita H, Manabe T, Ohtsuka T, Shimamoto M, Miyazaki T,
et al: Suppression of CD51 in pancreatic stellate cells inhibits
tumor growth by reducing stroma and altering tumor-stroma
interaction in pancreatic cancer. Int J Oncol. 48:1499–1508. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang B, Ye H, Ren X, Zheng S, Zhou Q,
Chen C, Lin Q, Li G, Wei L, Fu Z, et al: Macrophage-expressed CD51
promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in
pancreatic cancer. Cancer Lett. 459:204–215. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mattila E, Pellinen T, Nevo J, Vuoriluoto
K, Arjonen A and Ivaska J: Negative regulation of EGFR signalling
through integrin-alpha1beta1-mediated activation of protein
tyrosine phosphatase TCPTP. Nat Cell Biol. 7:78–85. 2005.
View Article : Google Scholar
|
|
26
|
Alday-Parejo B, Stupp R and Rüegg C: Are
integrins still practicable targets for anti-cancer therapy?
Cancers (Basel). 11:9782019. View Article : Google Scholar
|
|
27
|
Woodard GA, Ray KM, Joe BN and Price ER:
Qualitative radiogenomics: Association between oncotype DX test
recurrence score and BI-RADS mammographic and breast MR imaging
features. Radiology. 286:60–70. 2018. View Article : Google Scholar
|
|
28
|
Zhou M, Leung A, Echegaray S, Gentles A,
Shrager JB, Jensen KC, Berry GJ, Plevritis SK, Rubin DL, Napel S
and Gevaert O: Non-small cell lung cancer radiogenomics map
identifies relationships between molecular and imaging phenotypes
with prognostic implications. Radiology. 286:307–315. 2018.
View Article : Google Scholar
|
|
29
|
Attiyeh MA, Chakraborty J, Doussot A,
Langdon-Embry L, Mainarich S, Gönen M, Balachandran VP, D'Angelica
MI, DeMatteo RP, Jarnagin WR, et al: Survival prediction in
pancreatic ductal adenocarcinoma by quantitative computed
tomography image analysis. Ann Surg Oncol. 25:1034–1042. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu P, Gu Q, Hu X, Tan X, Liu J, Xie A and
Huang F: Applying a radiomics-based strategy to preoperatively
predict lymph node metastasis in the resectable pancreatic ductal
adenocarcinoma. J Xray Sci Technol. 28:1113–1121. 2020.PubMed/NCBI
|
|
31
|
Xie T, Wang X, Li M, Tong T, Yu X and Zhou
Z: Pancreatic ductal adenocarcinoma: A radiomics nomogram
outperforms clinical model and TNM staging for survival estimation
after curative resection. Eur Radiol. 30:2513–2524. 2020.
View Article : Google Scholar : PubMed/NCBI
|
